Dermatology Online Journal · 2015 · 26 citations · 10 references
MedicineDermatologyPharmacotherapyImmunotherapyInflammationRheumatologyAutoimmune DiseasesAutoimmune Rheumatic DiseasesInflammatory Disease PharmacotherapyInflammatory Skin DiseasesPsoriatic ArthritisBiologic Anti-inflammatory AgentsBiologic EfficacyClinical RemissionCombination TherapyPsoriasis TherapyPsoriatic DiseaseRemission Induction TherapySide Effect Profile
Psoriasis is a chronic immune-mediated inflammatory condition that affects 2-3% of the population. Apremilast was FDA-approved in March 2014 for the treatment of psoriatic arthritis and in September 2014 for the treatment of moderate to severe plaque psoriasis. Apremilast appears to have lower efficacy than some biologic agents such as adalimumab and ustekinumab, which achieve a PASI-75 in approximately 70% of patients after 12-16 weeks of therapy. However, its ease of administration as an oral agent coupled with a mild side effect profile make it an attractive option for psoriasis treatment. Herein, we present a patient with a 17-year history of plaque type psoriasis recalcitrant to topical, oral, and biologic mediations who attained near-complete remission after therapy with a combination of adalimumab and apremilast.
10
Craig L. Leonardi, Alexa B. Kimball, Kim Papp et al. · The Lancet · 2008 · 1.9K citations
Medicine, Dermatology, Immunology +15
Kim Papp, Richard G. Langley, Mark Lebwohl et al. · The Lancet · 2008 · 1.4K citations
Medicine, Dermatology, Immunology +15
Kenneth B. Gordon, Richard G. Langley, Craig L. Leonardi et al. · Journal of the American Academy of Dermatology · 2006 · 507 citations
Medicine, Dermatology, Immunology +10
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity
Peter Schäfer, Anastasia Parton, Lori Capone et al. · Cellular Signalling · 2014 · 306 citations · Full text
Medicine, Immunology, Pharmacology +17